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Activation of Hypoxia-Inducible Factor-2 in Adipocytes Results in
Pathological Cardiac Hypertrophy
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Background-—Obesity can cause structural and functional abnormalities of the heart via complex but largely undeﬁned
mechanisms. Emerging evidence has shown that obesity results in reduced oxygen concentrations, or hypoxia, in adipose tissue.
We hypothesized that the adipocyte hypoxia-signaling pathway plays an essential role in the development of obesity-associated
cardiomyopathy.
Methods and Results-—Using a mouse model in which the hypoxia-inducible factor (HIF) pathway is activated by deletion of the
von Hippel–Lindau gene speciﬁcally in adipocytes, we found that mice with adipocyte–von Hippel–Lindau deletion developed lethal
cardiac hypertrophy. HIF activation in adipocytes results in overexpression of key cardiomyopathy-associated genes in adipose
tissue, increased serum levels of several proinﬂammatory cytokines including interleukin-1b and monocyte chemotactic protein-1,
and activation of nuclear factor–jB and nuclear factor of activated T cells in the heart. Interestingly, genetic deletion of Hif2a, but
not Hif1a, was able to rescue cardiac hypertrophy and abrogate adipose inﬂammation.
Conclusion-—We have discovered a previously uncharacterized mechanism underlying a critical and direct role of the adipocyte
HIF-2 transcription factor in the development of adipose inﬂammation and pathological cardiac hypertrophy. ( J Am Heart Assoc.
2013;2:e000548 doi: 10.1161/JAHA.113.000548)
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O bese patients often develop cardiomyopathy withincreased wall thickness and cavity volume of the left
ventricle.1 Amad et al2 reported that increase in heart weight
above the predicted normal value was almost proportional to
the increase of body weight over the normal range and that
the predominant and most speciﬁc alteration in the hearts of
grossly obese persons was ventricular hypertrophy. Although
the exact mechanisms by which obesity contributes to
changes in cardiac structure and function remain to be fully
elucidated, obesity-induced changes in adipose tissue func-
tions, especially abnormal metabolism and chronic inﬂamma-
tion, are thought to play a critical role in the development of
heart disease.3,4 Deciphering the mechanisms by which
adipose tissue can have these critical effects on the heart,
an anatomically separate organ, is of high clinical signiﬁcance.
Emerging evidence has shown that adipose tissues in
obese mice and humans become hypoxic or oxygen deﬁ-
cient.5–7 Direct PO2 measurement has revealed an average
PO2 of 15.2 mm Hg in adipose tissue of ob/ob mice,
compared with 47.9 mm Hg in that of lean mice.6 In a cohort
of overweight or obese patients, the mean adipose PO2 is
15% lower than that of the lean subjects and decreases
further with increasing body fat percentage.5 Previously, we
found that hypoxia directly regulates adipocyte differentiation
and function.8,9 Others have found that hypoxia exerts a
strong impact on glucose and lipid metabolism, as well as the
production of adipokines and inﬂammatory cytokines in
adipose tissue.5,6 These observations suggest a possible
mechanistic sequence in which obesity leads to hypoxia-
mediated changes in adipose tissue biology that in turn effect
pathological abnormalities in remote tissues and organs,
including the heart.
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The most prominent O2-sensing mechanism in mammalian
cells is manifested by transcription activities of the hypoxia-
inducible factors (HIF) consisting of an O2-sensitive HIF-a
(HIF-1a or HIF-2a) and the O2-insensitive HIF-1b subunit.
10
Under normoxic conditions, HIF-a becomes hydroxylated by
prolyl hydroxylases, and the hydroxylated HIF-a is degraded
by proteasomes via interaction with the von Hippel–Lindau
protein (pVHL).11 When hydroxylation of HIF-a is inhibited by
hypoxia (eg, <2% O2), HIF-a becomes stabilized and dimerizes
with the constitutively expressed HIF-1b to activate tran-
scription of a wide range of genes, including those involved in
the regulation of angiogenesis and energy metabolism.10,12
Recent studies have also suggested a role of the HIF pathway
in obesity, diabetes, and metabolic syndrome.13
We found that Hif1a is expressed in both mature adipocytes
and progenitor cells and that activation of HIF-1 inhibits
adipogenic differentiation.8,9 In contrast, Hif2a is expressed in
differentiated adipocytes but not in preadipocytes,8 suggesting
a speciﬁc role of HIF-2a in mature adipocytes. Interestingly,
adipose tissue from obese mice shows elevated levels of HIF-
1a6 and increased HIF DNA-binding activities.7 Increased levels
of HIF-2a protein have also been found in mouse adipose tissue
after 4 weeks of a high-fat diet.14 These observations not only
provide additional evidence regarding adipose hypoxia but also
suggest an important role of HIF-1a and/or HIF-2a in the
regulation of biological functions of adipose tissue.
We investigated whether HIF activation in adipocytes effects
pathological changes in the heart using tissue-speciﬁc gene
targeting in mice. We show here that adipocyte-speciﬁc
activation of the HIF-pathway results in pathological cardio-
megaly featuring myocardial hypertrophy, left ventricular dila-
tion, and cardiac contractile dysfunction. The cardiac phenotype
is correlated with marked HIF-induced adipose tissue inﬂam-
mation and activation of the prohypertrophy pathwaysmediated
by nuclear factor–jB (NF-jB) and nuclear factor of activated T
cells (NFAT) in the heart. Interestingly, we ﬁnd that adipocyte
HIF-2a, not HIF-1a, plays an essential role in the development of
fatal cardiac hypertrophy. These data support a model in which
activation of HIF-2a in adipocytes leads to increased production
of adipose tissue–derived inﬂammatory cytokines that, together
with other adipocyte-derived factors, drive pathological changes
in remote tissues such as the heart. This previously unappre-
ciated mechanistic link can be potentially exploited for clinical
intervention of obesity-associated cardiomyopathy or other
related metabolic syndromes.
Methods
Generation and Analysis of Mice
Transgenic mice with ﬂoxed Vhl,15 Hif1a,16 or Hif2a17 alleles
were crossed with aP2/Fabp4-Cre mice18 to create adipose-
speciﬁc knockout (KO) mice. The aP2/Fabp4-Cre mice had
been subsequently backcrossed into the C57BL/6 background
for >10 generations. Cre-mediated recombination of Vhl in
adipocytes was accomplished by generating mice that were
homozygous for the ﬂoxed (2-lox) Vhl alleles and expressed the
aP2/Fabp4-Cre transgene. Littermates without the cre trans-
gene were used as control animals. Primer sequences used to
detect the aP2/Fabp4-Cre transgene as well as the nonrecom-
bined (2-lox), recombined (1-lox), and wild-type (WT) alleles for
Vhl have been previously described.15,18 All animal procedures
were performed in accordance with the National Institutes of
Health guidelines for the use and care of live animals and were
approved by the Institutional Animal Care and Use Committee
of Yale University.
Mice were killed via carbon dioxide asphyxiation, blood
was collected via cardiac puncture, and tissues were ﬁxed in
either 10% neutral buffered formalin or Bouin’s ﬁxative (Ricca
Chemical Corporation). Tissues were trimmed, processed,
embedded, and sectioned and stained for hematoxylin and
eosin by routine methods. Mice underwent necropsy, and
tissues were examined in a manner blind to experimental
genotype. For Oil Red O staining, frozen tissue sections were
ﬁxed in formalin and then stained in an Oil Red O solution as
described previously.8,19 Tissues were counterstained with
hematoxylin for microscopy.
Peripheral Blood Analysis
Hematology assays (Advia 120 Hematology Analyzer, Bayer
Diagnostic Systems) were performed according to standard
methods at Antech Diagnostics.
Macrophage Preparation
Mice received a daily intraperitoneal injection of 4 mg/mL
Brewer Thioglycollate (SigmaAldrich) solution at a rate of 1 mL/
mouse for 3 consecutive days. Aftermicewere killedwhile under
anesthesia, intraperitoneal macrophages were collected by
injecting 10 mL cold PBS into the intraperitoneal cavity.
Immunohistochemical Analysis
Immunohistochemical analysis was performed on tissue
sections mounted on charged slides (Colormark plus slides,
Thermo Scientiﬁc). Brieﬂy, the slides were deparafﬁnized in
xylene and rehydrated through graded ethanol to distilled
water. Antigen retrieval for Ki67 was performed by steam
treatment in a food steamer (Oster 5715) using a 10-mmol/L
citrate buffer for 20 minutes and then cooled to room
temperature. For anti–factor VIII staining, sections were
treated with proteinase K for 5 minutes at room temperature.
Slides were rinsed in distilled water and placed in Tris-
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buffered saline (TBS) and then immersed in 3% hydrogen
peroxide (H2O2) and distilled water for 5 minutes to block
endogenous peroxidase activity. Following a TBS rinse, the
primary antibodies anti–von Willebrand factor (1:2500, Dako)
or anti-Ki67 (1:200, Biocare Medical) were applied and
incubated for 30 minutes in a humidiﬁed chamber at room
temperature. After a TBS rinse, secondary detection was
performed using the Envision Kit (Dako) with the chromogen
diaminobenzedine tetrahydrochloride (DAB; Dako). The slides
were then rinsed in distilled water and counterstained with
hematoxylin. Finally, they were dehydrated, cleared in xylene,
and coverslipped with a resinous mounting media. Apoptosis
was analyzed by terminal deoxynucleotidyl transferase dUTP
nick end labeling staining (Millipore). All immunohistochem-
ical procedures were performed at the Research Histology
Laboratory in the Department of Pathology, Yale School of
Medicine.
Gene Expression Analysis Using cDNA
Microarrays
RNA was isolated from interscapular fat pads using the TriZOL
Reagent according to the manufacturer’s protocols (Invitro-
gen). The quality of total RNA (A260/A280 ≥1.9) was validated
by using electrophoresis with the Agilent Bioanalyzer. Gene
expression was analyzed using the Affymetrix Mouse Gene
1.0 ST Array at the Yale Center for Genomic Analysis. Genes
were considered to be upregulated or downregulated if the
relative expression was changed 2-fold or greater above the
WT control. Rigorous statistical analyses to identify differen-
tially regulated genes were performed at the Keck Bioinfor-
matics Resource. A statistically signiﬁcant difference was
declared when the false discovery rate–adjusted value of
P<0.05.
RT-PCR
RNA was isolated using the Trizol Reagent according to the
manufacturer’s protocols (Invitrogen). DNase I–treated RNA
was used for ﬁrst-strand cDNA synthesis using the High
Capacity cDNA Reverse Transcription Kit (Applied Biosys-
tems). Real-time PCR was performed on StepOne Plus
(Applied Biosystems) using either Power SYBR Green PCR
Master Mix or TaqMan Gene Expression Master Mix (Applied
Biosystems). The primer and probe sets used to amplify
speciﬁc target genes can be found in Tables 1 and 2.
Western Blot Analysis
Protein extracts were prepared from freshly harvested tissues
in RIPA buffer containing protease inhibitors. Primary anti-
bodies for Western blot analysis included polyclonal rabbit
anti-HIF-1a (R&D Systems), mouse monoclonal anti-HIF2a
(Santa Cruz Biotechnology), rabbit anti-NF-jB p105/p50
(Santa Cruz Biotechnology), rabbit anti–NF-jB p65 (Santa
Cruz Biotechnology), rabbit anti-GAPDH (Cell Signaling), and
mouse monoclonal anti–b-actin (Sigma Aldrich). Protein
bands were visualized by using enhanced chemiluminescence
(Perkin Elmer).
Quantitative Multiplexed Cytokine Assay
Mouse blood was drawn via cardiac puncture. Cytokines in
sera were analyzed by the CytoPlex-Multiplex Core Facility of
Yale School of Medicine using the Bio-Plex Pro Mouse
Cytokine 15-plex Assay (Bio-Rad) for interleukin (IL)-1a, IL-1b,
IL-6, IL-10, IL-12p40, IL-12-p70, granulocyte colony-stimulat-
ing factor, granulocyte-macrophage colony-stimulating factor,
interferon-c (IFNc), KC (keratinocyte-derived chemokine or
CXCL1), monocyte chemotactic protein-1 (MCP-1), macro-
phage inﬂammatory protein (MIP)-1a, MIP-1b, regulated upon
activation normal T cell expressed and presumably secreted
(RANTES), and tumor necrosis factor (TNF)-a. Concentration
standards were ﬁtted to Brendan’s 5-parameter logistic
curve.
Metabolic Characterization
For glucose tolerance tests, mice were fasted overnight for
14 to 16 hours and then received an intraperitoneal injection
of glucose at 2 mg/kg body weight. Blood glucose levels
were measured using a glucose meter (OneTouch Ultra)
before and at 15, 30, 60, and 120 minutes after glucose
injection. For insulin tolerance tests, postprandial mice
received an intraperitoneal injection of insulin at 0.75 U/kg
body weight. Blood glucose levels were measured using a
glucose meter before and at 15, 30, 60, and 120 minutes
after insulin injection. Triglyceride Determination Kit (Sigma
Aldrich) was used to determine serum glycerol and triglyc-
eride concentrations from nonfasting mice (male and female),
as well as plasma-free fatty acid concentrations from fasting
female mice according the manufacturer-recommended pro-
tocols.
Analysis of Cardiomyocyte Sizes
Cross sections (7 lm) of mouse heart were cut from frozen
OCT-embedded blocks and ﬁxed in cold acetone. After
blocking in PBS containing 3% BSA, tissue sections were
incubated for 1 hour at room temperature with 50 lg/mL
FITC-conjugated lectin (Sigma Aldrich) that preferentially
binds glycoproteins. Cross-sectional areas of individual car-
diomyocytes were measured using NIH ImageJ (National
Institutes of Health).
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Transmission Electron Microscopy
Mouse heart was perfused with 2.5% gluteraldehyde in
0.1 mol/L HEPES, pH 7.2. Trimmed left ventricle tissues
were ﬁxed in 2.5% gluteraldehyde in 0.1 mol/L sodium
cacodylate. After being rinsed in sodium cacodylate, heart
Table 1. Primers for SYBR Green PCRs
Gene RefSeq Primers
Adm NM_009627 Forward: CACCCTGATGTTATTGGGTTCA
Reverse: TTAGCGCCCACTTATTCCACT
Angptl3 NM_013913 Forward: GCCCTCCCAGAGCACACAGAC
Reverse: TCCACCACCAGCCACCTGAGT
Apoa5 NM_080434 Forward: GACTACTTCAGCCAAAA
CAGTTGGA
Reverse: AAGCTGCCTTTCAGGTTCTCCT
Apoc4 NM_007385 Forward: TGTCTACAGAAAGCCT
GAGCCCCA
Reverse: CTCCAGGGCCCCAGAACCACT
Apom NM_018816 Forward: CCATCCGCACGAAAAGTGGGGT
Reverse: TGTCTGGGCGCCCTTCAGTTCT
Ccl2 NM_011333 Forward: GCCAGCTCTCTCTTCCTCCACCA
Reverse: GGGCGTTAACTGCATCTGGCTGA
Ccl3 NM_011337 Forward: ATGGAGCTGACACCCCGACTGC
Reverse: TCAGGAAAATGACACC
TGGCTGGGA
Ccl7 NM_013654 Forward: CAACCAGATGGGCCCAAT
GCATCC
Reverse: AGCTTCCCAGGGACACCGACT
Ccl8 NM_021443 Forward: TGGGCCAGATA
AGGCTCCAGTCA
Reverse: AACCACAGCTT
CCATGGGGCACT
Col1a1 NM_007742 Forward: AGGCTTCAGTGGTTTGGATG
Reverse: CACCAACAGCACCATCGTTA
Ctgf NM_010217 Forward: CAAAGCAGCTGCAAATACCA
Reverse: GGCCAAATGTGTCTTCCAGT
Egln3 NM_028133 Forward: AGGCAATGGTGGCTTGCTATC
Reverse: GCGTCCCAATTCTTATTCAGGT
Fgf10 NM_008002 Forward: TTTGGTGTCTTCGTTCCCTGT
Reverse: TAGCTCCGCACATGCCTTC
Gpd2 NM_010274 Forward: GAAGGGGACTATTCTTGTGGGT
Reverse: GGATGTCAAATTCGGGTGTGT
Glut3 NM_011401 Forward: ATGGGGACAACGAAGGTGAC
Reverse: GTCTCAGGTGCATTGATGACTC
Gyk NM_008194 Forward: GGGTTGGTGTGTGGAGTCTTG
Reverse: GATTTCGCTTTCTTCAGCATTGA
Hmox1 NM_010442 Forward: GCCACCAAGGAGGTACACAT
Reverse: GCTTGTTGCGCTCTATCTCC
Hprt NM_013556 Forward: AGTGTTGGATACAGGCCAGAC
Reverse: CGTGATTCAAATCCCTGAAGT
Ifi27l2a NM_029803 Forward: CAGCTGCCTCCATAGCAGCCAAG
Reverse: GGAGAGTCCAAGGA
CCCCTGCT
Lep NM_008493 Forward: GGGCTTCACCCCATTCTGA
Reverse: AGGCTGGTGAGGACCTGTTG
Myh6 NM_010856 Forward: AAGGCAAGGCCAAGAACGCC
Reverse: AGCTCAGCCTTGGCCTCCAT
Continued
Table 1. Continued
Gene RefSeq Primers
Myh7 NM_080728 Forward: ATGAGCAAGCCCTGGGCAGT
Reverse: AGAGCGCAGCTTCTCCACCT
Nppa NM_008725 Forward: AACTGAGGGCTCTGCTCGCT
Reverse: TTCGGTACCGGAAGCTGTTGC
Nfatc1 NM_016791 Forward: TCGAGTGTTCCCAGCGGTCA
Reverse: GCACAGGTCCCGGTCAGTCT
Nfatc2 NM_010899 Forward: ATCCGCGTGCCCGTGAAAG
Reverse: TCTTGATGGCAGGGACTGGGT
Nfatc3 NM_010901 Forward: GAGTGCTCTCAGCGATCTGCTC
Reverse: TCCTTCAGCCTCCCAAT
GAGGTC
Nfatc4 NM_023699.3 Forward: CACCCTGGAGGAAGTGA
GTGAGATC
Reverse: GGGGCTTCGGGGACCACTAC
Osf2 NM_015784 Forward: CTGGTATCAAGGTGCTATCTGC
Reverse: AAACATGGTCAATAGGC
ATCACT
Plgf NM_008827 Forward: TCTGCTGGGAACAACTCAACA
Reverse: GTGAGACACCTCATCAGGGTAT
Ppargc1a NM_008904 Forward: GGACAGTCTCCCCGTGGAT
Reverse: TCCATCTGTCAGTGCATCAAATG
Rcan1-1 NM_001081549 Forward: GAGGAGGTGGATCTGCAGGACCT
Reverse: CACAGGCCGTCCACGAACACG
Rcan1-4 NM_019466 Forward: TCGTTAAGCGTCTGCCCCGTG
Reverse: GCCACACAAGCAATCAG
GGAGCT
Serpine1 NM_008871 Forward: TGCAACCCTGGCCGACTTCA
Reverse: CGGGCTGAGATGACAAA
GGCTGT
Thbs1 NM_011580 Forward: GGGGAGATAACGGTGTGTTTG
Reverse: CGGGGATCAGGTTGGCATT
Vcam1 NM_011693 Forward: TGCCGAGCTAAATTACACATTG
Reverse: CCTTGTGGAGGGATGTACAGA
Vegfd NM_010216 Forward: TTGAGCGATCATCCCGGTC
Reverse: GCGTGAGTCCATACTGGCAAG
18S rRNA NR_003278 Forward: CGGACAGGATTGACAGATTG
Reverse: CAAATCGCTCCACCAACTAA
Nd2 Genomic,
mitochondrial
Forward: CCCATTCCACTTCTGATTACC
Reverse: ATGATAGTAGAGTTGAGTAGCG
PolB Genomic,
nuclear
Forward: CCCTCTTCCTCTTCATTATAT
CTCC
Reverse: CCTCAACTCCACCACAACAC
Speciﬁcity of the primers was validated using NCBI Primer-BLAST.
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tissues were incubated in 1% osmium tetroxide for 1 hour, en
bloc stained in 2% uranyl acetate in maleate buffer pH 5.2 for
an additional hour, and then rinsed, dehydrated in an ethanol
series and inﬁltrated with resin (Embed812 EMS), and baked
overnight at 60°C. Hardened blocks were cut using a Leica
UltraCut UCT. Sixty-nanometer sections were collected on
grids and stained using uranyl acetate and lead citrate.
Samples were viewed on FEI Tencai Biotwin TEM at 80 kV
(CCD and iTEM software; Olympus). Sample preparation and
transmission electron microscopy were performed at the EM
Core Facility of Yale School of Medicine.
Cardioechography
Mice were anesthetized with 1% isoﬂurane in oxygen and then
placed on a heated procedure board with temperature main-
tained at 37°C. During the procedure, mice were kept anesthe-
tizedwith 1% isoﬂurane supplied by a nose cone connected to an
isoﬂurane vaporizer. Stable sonographic images and data (both
B and M mode) were acquired and analyzed using Vevo 770
(VisualSonics). Systolic and diastolic left ventricle wall thick-
nesses and chamber dimensions were measured using M-mode
images. Ejection fraction (EF in %) and fractional shortening (FS
in %) were calculated using the included software.
Pressure–Volume Analysis
Mice were anesthetized with an intraperitoneal injection of
ketamine (100 mg/kg body weight) and xylazine (5 mg/kg)
and placed on a heated pad to maintain body temperature at
37°C. The trachea was orally intubated and connected to a
volume-controlled ventilator at a respiratory rate of
100 breaths/min with room air. A 1.2-French conductance
pressure–volume catheter (Scisense) was inserted via the
right carotid artery to measure left ventricular (LV) function.
LV pressure and volume signals were continuously monitored
and digitally recorded at 1000 Hz (Sciences Inc). Baseline
hemodynamic parameters were recorded for 10 minutes
following 10-minute stabilization after surgical preparation.
Mean blood pressure, LV peak pressure, and high-ﬁdelity
positive and negative dP/dt (dP/dtmax and dP/dtmin) values
were calculated using the analysis software LabScribe2
(iWorx, CB Sciences Inc)
Statistical Analysis
Ordinary 1-way ANOVA was used for comparison among 3 or
more groups, and post hoc Dunnett’s multiple comparison
test was performed where applicable. For data with non-
Gaussian distribution (see later, Figure 11F and 11G),
Kruskal–Wallis 1-way ANOVA was used with post hoc Dunn’s
multiple-comparison test. The unpaired Student’s t-test was
used for comparison between 2 groups. Data were shown as
meanSEM. The log-rank test was used for analyzing survival
data. A value of P<0.05 was considered statistically signiﬁ-
cant. All statistical analyses were performed using Prism 6
(GraphPad Software, Inc)
Results
Adipocyte-Speciﬁc HIF Activation Results in
Lethal Cardiomegaly
Loss of pVHL leads to HIF activation,11 which provides a
genetic approach to mimic hypoxia signal transduction. We
therefore created a genetic mouse model (fatVHLko, Figure 1)
with adipocyte-speciﬁc inactivation of Vhl by crossing the Vhlf/f
mice with the transgenic mice carrying the cre recombinase
driven by the adipocyte-speciﬁc aP2/Fabp4 promoter devel-
oped by Dr Barbara Kahn.18 The cre-mediated recombination
occurred speciﬁcally in both interscapular brown (BAT) and
perigonadal white (WAT) adipose tissue with no detectable cre-
mediated recombination in other tissues, including heart,
brain, liver, macrophages, and skeletal muscle (Figures 1A and
1B and 2A and 2B). Consistently, other groups have also
reported highly adipocyte-speciﬁc recombination in this par-
ticular aP2/Fabp4-cre transgenic mouse strain.18,20–22
Morphologically, the majority of BAT and WAT adipocytes
of the homozygous fatVHLko mice were enlarged (Figure 1C),
likely due to increased glucose uptake and intracellular lipid
accumulation resulting from HIF activation,10,12,15,23 which
also indicates highly efﬁcient cre-mediated recombination in
adipocytes. Western blots showed robust accumulation of
HIF-1a and HIF-2a proteins in both BAT and WAT of fatVHLko
mice (Figures 1D and 2C), further conﬁrming HIF activation in
fatVHLko adipose tissue.
Table 2. Primers for TaqMan-Based PCRs From Applied
Biosystems
Gene Assay ID RefSeq
Emr1 Mm01233103_m1 NM_010130.4
Hif1a Mm00468869_m1 NM_010431.2
Hif2a Mm00438717_m1 NM_010137.3
Il1b Mm00434228_m1 NM_008361.3
Il6 Mm00446190_m1 NM_031168.1
Mif Mm01611157_gH NM_010798.2
Mmp9 Mm00442991_m1 NM_013599.2
Tgfb Mm00441724_m1 NM_011577.1
Tnf Mm00443258_m1 NM_013693.2
Vegfa Mm01281449_m1 NM_001025250
18S rRNA 4319413E X03205.1
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Homozygous fatVHLko mice were born with an expected
Mendelian ratio and showed no gross developmental defects
at birth. Both male and female mice appeared to have normal
development of interscapular fat. However, visceral fat was
generally reduced (Figure 2D and 2E), suggesting a depot-
dependent effect of HIF activation on adipose development.
Because the gross development of the interscapular fat pad
was similar in both female and male fatVHLko mice, we
reasoned that biological changes induced by Vhl-deletion in
interscapular fat would be underscored by common mecha-
nisms in a sex-independent manner. By gene expression
analysis, we found that many of the known HIF targets24 were
signiﬁcantly upregulated in fatVHLko fat (Figure 1E and
Table 3). Importantly, among the upregulated genes, Hmox1,
Lep, Serpine1/Pai1, and Vegfd/Figf are also increased in
obese mice and humans.6,25 However, Vegfa was not
signiﬁcantly changed in fatVHLko mice, similar to observa-
tions in ob/ob mice.6 Collectively, these data demonstrate
that adipocyte-speciﬁc Vhl deletion leads to activation of the
HIF pathway and increased expression of several key obesity-
associated genes.
Postnatally, fatVHLko mice developed cardiomegaly within
the ﬁrst week of life, which coincides with the rapid postnatal
development of adipose tissue.26 Compared with WT litter-
mates, the homozygous KO mice did not vary in body weight
(Figure 3A), and most organs appeared grossly normal at
necropsy except for signiﬁcant cardiomegaly with enlarged
ventricular sizes and wall thicknesses (Figure 4; later, see
Figure 7) in every single KO mouse examined. Immunohisto-
chemical von Willebrand factor staining showed dramatically
increased cardiac angiogenesis (Figure 4C and 4D). Increased
angiogenesis was also found in other tissues (data not
Figure 1. Generation of the mouse model with adipocyte-speciﬁc Vhl deletion. A, End point PCR conﬁrms the speciﬁc Vhl recombination (1-Lox)
in perigonadal white (WAT) and interscapular brown (BAT) fat of fatVHLko mice with fatVHLwt littermates as the wild-type (WT) control.
B, Quantitative real-time PCR shows robust increases of the recombined Vhl allele (1-Lox) in WAT, BAT, skeletal muscle (SM), and tail of fatVHLko
mice. C, Histochemical (H&E, scale=50 lm) analysis shows enlarged WAT and BAT cells from fatVHLko mice. Arrows indicate blood vessels.
D, Western blots show strong accumulation of HIF-1a and HIF-2a proteins in WAT and BAT of fatVHLko mice. E, Expression of selective hypoxia-
inducible genes in interscapular fat pad is analyzed by qRT-PCR (n=3, *P<0.05 vs fatVHLwt, t-test). Adm indicates adrenomedullin; BAT, brown
adipose tissue; Egln3, EGL nine homolog 3; H&E, hematoxylin and eosin; HIF, hypoxia-inducible factor; Hmox1, heme oxygenase 1; Lep, leptin;
qRT-PCR, quantitative real-time polymerase chain reaction; Thbs1, thrombospondin 1; VHL, von Hippel–Lindau; WAT, white adipose tissue.
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shown), suggesting elevated secretion of proangiogenic
cytokines by fatVHLko adipocytes. However, fatVHLko mice
showed normal hematocrit, hemoglobin concentration, and
red blood cell counts (Figure 3B through 3D), suggesting that
deletion of Vhl in adipocytes does not alter erythropoiesis. The
sizes of fatVHLko cardiomyocytes were signiﬁcantly increased
compared with WT cells (Figure 4E). There were also signif-
icantly higher numbers of Ki67+ cells but not appreciable
changes in apoptosis, as shown by terminal deoxynucleotidyl
transferase dUTP nick end labeling staining, in the heart of
fatVHLko mice compared with their WT littermates (Figure 4F
and 4G). However, it is possible that the Ki67+ cells may also
Figure 2. Speciﬁcity of aP2-cre–mediated Vhl recombination in adipocytes. A, No signiﬁcant Vhl recombination was found in heart, liver, and
skeletal muscle. DNA was made from indicated tissues. The ﬂoxed Vhl alleles before (2-Lox) and after (1-Lox) recombination were detected by
PCR as described in Methods. B, No signiﬁcant Vhl recombination was found in macrophages. Genomic DNA was prepared from interscapular fat
pad (BAT), perigonadal fat pad (WAT), or thioglycollate-induced peritoneal macrophages. The recombination product (Vhl 1-lox) was measured by
quantitative PCR. C, Speciﬁc accumulation of HIF-1a and HIF-2a proteins in both WAT and BAT of fatVHLko mice was conﬁrmed by Western
blotting. No accumulation of HIF-1a was observed in skeletal muscle and liver. No accumulation of HIF-2a was observed in skeletal muscle. Note
that HIF-2a was constitutively expressed in liver. D and E, Visceral adiposity (WAT) in fatVHLko mice was generally reduced in comparison to their
wild-type littermates, whereas weight of interscapular fat (BAT) did not change signiﬁcantly (6 to 10 weeks old). *P<0.05 (t-test) compared with
fatVHLwt, n=3 (male), n=5 (female). BAT indicates brown adipose tissue; HIF, hypoxia-inducible factor; KO, knockout; PCR, polymerase chain
reaction; VHL, von Hippel-Lindau; WAT, white adipose tissue; WT, wild type.
Table 3. A Selective List of Hypoxia-Inducible Genes Differentially Regulated in fatVHLko Adipose Tissue (n=3)
Gene Symbol Gene Name NCBI Accession FDR Adjusted P Value Fold-Change (KO vs WT)
Hmox1 Heme oxygenase 1 NM_010442 0.0064 5.54
Thbs1 Thrombospondin 1 NM_011580 0.0039 4.86
Serpine1 Plasminogen activator inhibitor-1 (PAI-1) NM_008871 0.0067 4.70
Adm Adrenomedullin NM_009627 0.0059 3.80
Aldh3b2 Aldehyde dehydrogenase 3B2 NM_001177438 0.0110 3.73
Slc2a3 Solute carrier family 2 (facilitated glucose transporter) member 3 or Glut3 NM_011401 0.0069 3.26
Lep Leptin NM_008493 0.0471 3.08
Egln3 EGL (egg-laying abnormal) 9 homolog 3 (Caenorhabditis elegans) or
PHD3 (prolyl hydroxylase domain-containing 3)
NM_028133 0.0041 2.76
Upp1 Uridine phosphorylase 1 NM_009477 0.0109 2.27
Pgf Placental growth factor NM_008827 0.0380 2.03
FDR indicates false discovery rate; KO, knockout; NCBI, National Center for Biotechnology Information; WT, wild type.
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contain other cell types (ﬁbroblasts, endothelial cells, and/or
immune cells). Nonetheless, these results suggest that
cardiomegaly likely results from both hypertrophy and hyper-
plasia of cardiomyocytes. The median survival time of
fatVHLko mice is 10 weeks (Figure 4H). In contrast, Vhl
heterozygous mice showed no pathological symptoms.
Several mouse models27 have been generated with
conditional Vhl deletion in hepatocytes, endothelial cells,
and myeloid cells (including macrophages), respectively, but
none of them have developed cardiac defects. Previously, we
found that mice with conditional Vhl deletion in cardiomyo-
cytes developed cardiac defects by 5 months of age.23 In
contrast, our fatVHLko mice in this study exhibited cardio-
megaly by postnatal day 7. Furthermore, consistent with other
reports,18,20–22 no signiﬁcant recombination of Vhl alleles, nor
accumulation of HIF-a protein, was observed in the heart
(Figures 2A and 3E). There was also no intracellular lipid
accumulation in cardiomyocytes or hepatocytes (Figure 3F), a
prominent phenotype of Vhl deletion in these tissues.15,23
Consistently, electron microscopic examination also did not
show abnormal fat accumulation in cardiomyocytes (Figure 5E).
Therefore, our fatVHLko mice developed the pathological
cardiac hypertrophy likely resulting from adipocyte-speciﬁc
Vhl deletion. In conclusion, this is the ﬁrst genetic model that
has clearly established adipocyte HIF activation as a signif-
icant cause of pathological cardiomegaly.
Adipocyte HIF-2 Is Required for the Development
of Cardiomegaly
The hypoxia-signaling pathway bifurcates to HIF-1 and HIF-2. We
investigated whether HIF-1a and HIF-2a are differentially
involved in the development of pathological cardiomegaly using
a series of adipocyte-speciﬁc double- or triple-KO models
(Figure 5A). Not only did concomitant Hif1a deletion fail to
rescue the fatVHLko phenotype (Figure 5), but the median
survival time for fatVHL1Akomicewasonly4 weeks (Figure 4H).
Unexpectedly, adipocyte-speciﬁc Hif2a deletion completely
rescued the fatVHLko phenotypes including pathological cardio-
megaly (Figure 5) and adipose tissue development (Figure 6A
and 6B). Both fatVHL2Ako and fatVHL1A2Ako mice developed
normally and were healthy (Figure 4H). These data clearly
indicate that activation of HIF-2a, but not HIF-1a, in adipocytes
causes severe pathological changes inmice. Consistent with our
ﬁndings, a previous study showed that transgenic mice with
adipocyte-speciﬁc expression of a constitutively active HIF-1a
did not exhibit signiﬁcant cardiac abnormalities.7
Deletion of Vhl and double deletion of Vhl and Hif1a in
adipocytes strongly induced expression of several hypertro-
phic cardiomyopathy–associated genes (Figure 5D) including
connective tissue growth factor (Ctgf), atrial natriuretic factor
(Nppa), and myosin heavy-chain b (b-MHC or Myh7). In
contrast, concomitant Hif2a deletion by and large rescued the
Figure 3. Gross phenotypes and hematological parameters of fatVHLko mice. A, Body weight comparison of 6- to 8-week-old mice, n=7 to 9 per
group. Hematocrit (B), hemoglobin concentrations (C), and red blood cell (RBC) counts (D) of the peripheral blood of fatVHLko mice and wild-type
littermates (n=3 each, 6- to 8-week-old). No signiﬁcant statistical differences were found. (E) Increased accumulation of HIF-2a was found in
adipose tissue only by Western blot using tissue homogenates from fatVHLko (KO) and wild-type littermate controls (WT) with HIF-1b as loading
control. Results were validated in 3 pairs of KO and WT mice. F, Lack of fat accumulation (Oil Red O staining) in frozen sections of heart, liver, and
skeletal muscle from fatVHLko and wild-type mice. BAT and liver from a hepatocyte-speciﬁc Vhl knockout mouse were used as positive controls.
BAT indicates brown adipose tissue; HIF, hypoxia-inducible factor; SM, skeletal muscle; VHL, von Hippel–Lindau.
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Figure 4. Loss of Vhl in adipocytes results in defective cardiac development. A, Marked cardiomegaly in fatVHLko mice compared with wild-type
littermates. Scale=1 cm. B, Organ-to-body weight comparison (female and male combined) was performed using Student’s t-test. ***P<0.0001,
**P<0.002, fatVHLko (n=8) vs fatVHLwt (n=17). C, Histopathology of the heart indicates ventricular hypertrophy in fatVHLko mice compared with
fatVHLwt mice. Left (L) and right (R) ventricles are labeled (Top, H&E). Blood-ﬁlled vascular spaces are marked by * (middle, H&E). Blood vessels
are visualized by IHC using anti–von Willebrand factor (vWF, bottom). Scales=2000 lm (top) and 100 lm (middle and bottom). D, Numbers of
vWF+ cells per microscopic ﬁeld were counted (n=3, ***P<0.001 vs fatVHLwt, respectively, t-test). E, Cross-sectional areas of cardiomyocytes
(n=80, P<0.0001 1-way ANOVA; * indicates signiﬁcance vs fatVHLwt; # indicates signiﬁcance vs fatVHLko or fatVHL1Ako, Dunnett’s multiple
comparison test) measured from lectin-stained heart tissue sections. F, Ki67 IHC (DAB, hematoxylin; scale=50 lm) in left ventricular papillary
muscle (arrowheads). G, Cell counts for Ki67+ (n=3) or TUNEL+ (n = 4) cells in the heart per microscopic ﬁeld. *P<0.05 vs fatVHLwt (t-test).
H, Cumulative survival of fatVHLwt (n=19), fatVHLko mice (n=20), fatVHL1Ako (n=15), fatVHL2Ako (n=15), and fatVHL1A2Ako (n=12). P<0.0001
(log-rank test). Median survival (weeks): fatVHL1Ako=4, fatVHLko=10. Both female and male mice are included. DAB indicates diaminobenzedine;
H&E, hematoxylin and eosin; IHC, immunohistochemistry; KO, knockout; TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling;
VHL, von Hippel–Lindau; WT, wild type.
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Figure 5. Hif2a deletion rescues the cardiac phenotype in fatVHLko mice. A, Generation of Vhl single KO (fatVHLko), Vhl/Hif1a double KO
(fatVHL1Ako), Vhl/Hif2a double KO (fatVHL2Ako), and Vhl/Hif1a/Hif2a triple KO (fatVHL1A2Ako) mice, as shown by tail genotyping. Littermates
without aP2-cre were used as WT controls (fatVHLwt). B, Heart-to-body weight ratios (%). fatVHLwt: n=17; fatVHLko: n=9; fatVHL1Ako: n=6;
fatVHL2Ako: n=5; fatVHL1A2Ako: n=7. P<0.0001 (1-way ANOVA); *P<0.05 vs fatVHLwt; #P<0.05 vs fatVHLko or fatVHL1Ako (Dunnett’s multiple-
comparison test). C, Histopathology of the heart indicates correction of cardiomegaly (H&E) and angiogenesis (anti-vWF) in fatVHL2Ako and
fatVHL1A2Ako, but not in fatVHL1Ako mice. Scales: 2000 lm (H&E) and 100 lm (anti-vWF). D, Hif2a deletion reduces expression of hypertrophic
cardiomyopathy-associated genes in the heart, as shown by quantitative RT-PCR. For each gene category, P<0.02 (1-way ANOVA, fatVHLwt: n=6 to
7; fatVHLko: n=6 to 7; fatVHL1Ako: n=6 to 10; fatVHL2Ako: n=5; fatVHL1A2Ako: n=7 to 8). Signiﬁcant differences (P<0.05) within each gene
category: * vs WT, # vs fatVHLko or fatVHL1Ako, ^ vs fatVHLko. @ vs fatVHL1Ako (Dunnett’s multiple-comparison test). E, Electron microscopic
analysis of left ventricular muscle shows increased ﬁbrous deposits in fatVHLko and fatVHL1Ako hearts (right panel). F, Real-time PCR
quantiﬁcation of the mitochondrial NADH dehydrogenase 2 (Nd2) in hearts of transgenic mice. Nd2 levels were normalized to the nucleus-encoded
DNA polymerase b. P=0.014 (1-way ANOVA) with n=6 (fatVHLwt), 5 (fatVHLko), 6 (fatVHL1Ako), 7 (fatVHL2Ako), and 7 (fatVHL1A2Ako). HIF
indicates hypoxia-inducible factor; KO, knockout; VHL, von Hippel–Lindau; vWF, von Willebrand factor; WT, wild type.
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Figure 6. Hif2a deletion rescues the adipose tissue development and cardiac ﬁbrosis in fatVHLko mice. A, Ratios of fat pad-to-body weight were
analyzed using 1-way ANOVA and post hoc Dunnett’s multiple comparison test (n=17 for fatVHLwt, 8 for fatVHLko, 5 for fatVHL1Ako, 5 for
fatVHL2Ako, and 7 for fatVHL1A2Ako). The white fat group (WAT) showed signiﬁcant differences (P<0.001) especially with signiﬁcant reduction of
WAT in fatVHL1Ako mice compared with fatVHLwt. No differences were found in the BAT (interscapular fat) group. B, Angiogenesis was normalized
in fatVHL2Ako and fatVHL1A2Ako, but not in fatVHL1Ako fat pads in comparison to fatVHLwt. B, Paraﬁn-embeded interscapular brown fat pads
were stained with anti-vWF and counterstained with hematoxylin. C, Cardiac ﬁbrosis was analyzed using Masson’s trichrome staining. Gross
ﬁbrosis (blue stain) was found in both fatVHLko and fatVHL1Ako hearts. Adipocyte deletion of Hif2a (fatVHL2A and fatVHL1A2A) was sufﬁcient to
rescue cardiac ﬁbrosis. Scale bars=100 lm. BAT indicates brown adipose tissue; HIF, hypoxia-inducible factor; KO, knockout; VHL, von Hippel–
Lindau; vWF, von Willebrand factor; WAT, white adipose tissue; WT, wild type.
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abnormal expression of these cardiomyopathy-associated
genes resulting from the genetic deletion of VhlHif1a in
adipocytes. Using electron microscopy (Figure 5E), we found
that the cardiomyoﬁber formation appeared to be normal in all
KO models despite decreased ratios of a-MHC (Myh6):b-MHC
(Myh7) in fatVHLko and fatVHL1Ako hearts (Figure 5D).
Nonetheless, both fatVHLko and fatVHL1Ako hearts had
pronounced ﬁbrosis, whereas fatVHL2Ako and fatVHL1A2Ako
hearts showed no ﬁbrous deposits. Cardiac ﬁbrosis in the
hearts of fatVHLko and fatVHL1Ako mice was further
conﬁrmed by Masson’s trichrome staining (Figure 6C) and
was consistent with high levels of Ctgf and Osf2/Postn
(Figure 5D), markers of cardiac ﬁbrosis.28 In contrast,
increased expression of collagen Ia1 (Col1a1) was found in
fatVHLko hearts only (Figure 5D), suggesting both HIF-1a and
HIF-2a are required for producing adipocyte-derived factors
necessary for driving Col1a1 expression in the heart. None-
theless, these data clearly demonstrate that activation of
HIF-2 in adipocytes is also responsible for cardiac ﬁbrosis.
As shown by transmission electron microscopy examina-
tion, mitochondria structures in fatVHLko cardiomyocytes did
not signiﬁcantly differ from those in WT or Hif2a-KO cardio-
myocytes (Figure 5E). In addition, cardiac mitochondrial
biogenesis, as shown by the levels of mitochondrial NADH
dehydrogenase 2 (Nd2) gene, in fatVHLko mice was not
signiﬁcantly changed in these KO mice (Figure 5F). These
results suggest that cardiomyocyte mitochondrial formation
and functions are not strongly affected by HIF activation in
adipocytes and are not likely involved in the development of
pathological cardiomegaly under these conditions. However,
fatVHL1Ako heart did show mitochondrial fragmentation
(Figure 5E) and much reduced mitochondrial biogenesis
(40% reduction of Nd2 compared with fatVHLwt), which
might contribute to the more severely compromised heart
conditions and shorter life spans of fatVHL1Ako mice.
Activation of Adipocyte HIF-2 Impairs Cardiac
Structure and Function
Echocardiography and hemodynamic (catheter) assays were
performed on mice at 8 weeks of age, except that
fatVHL1Ako mice were 4 weeks old because of their short
life span. All mice appeared healthy at the time of
examination. Consistent with the morphological and histo-
logical analyses, dimensions of the LV and septum, as well
as LV mass, were signiﬁcantly increased in both fatVHLko
and fatVHL1Ako mice (Figure 7A and 7B). Again, cardiomeg-
aly was fully rescued on Hif2a deletion in fatVHL2Ako and
fatVHL1A2Ako mice (Figure 7A and 7B). Consistent with
these results, Hif2a deletion signiﬁcantly reduced cardio-
myocyte hypertrophy compared with both fatVHLko and
fatVHL1Ako cardiomyocytes (Figure 4E). Because there were
no signiﬁcant differences in heart rates and mean blood
pressures among all groups of mice under assay conditions
(Figure 8), these results suggest that HIF activation in
adipocytes results in lethal cardiac hypertrophy indepen-
dently of hypertension.
The fatVHLko and fatVHL1Ako hearts appeared to exhibit
variable functional defects. Although fatVHLko mice exhibited
higher LV volumes (LV end-diastolic and -systolic volumes)
but lower EFs (Figure 7C and 7D), fatVHL1Ako mice did not
show much change compared with their WT littermates
(Figure 7C and 7D), suggesting that Hif1a deletion can
correct LV volumes and stroke functions in fatVHLko mice.
From the hemodynamic perspective, fatVHLko and fat-
VHL1Ako mice showed relatively small decreases in end-
systolic pressure (Figure 7E) and in the rate of pressure
increase (+dP/dtmax, Figure 7G), although only fatVHLko
mice showed moderately higher end-diastolic pressure com-
pared with fatVHLwt (Figure 7F). Nonetheless, both fatVHLko
and fatVHL1Ako mice exhibited signiﬁcantly lower dP/dt
minimum (Figure 7H). Concomitant deletion of adipocyte
Hif2a was able to normalize dP/dt minimum (Figure 7H). By
and large, these KO mice did not develop severely defective
heart functions, which may reﬂect the relatively healthy state
of the mice at the time of investigation. It is nonetheless
possible that the prolonged pathological cardiomegaly sus-
tained by fatVHLko and fatVHL1Ako mice might lead to their
death, perhaps due to acute cardiac failure. Interestingly,
reports have shown that obese persons exhibit diastolic
dysfunction without hypertension29 and that they develop
ventricular hypertrophy and congestive heart failure without
other types of heart disease.2,30
Adipocyte HIF Activation Results in Abnormal
Lipid Metabolism
Glucose intolerance, insulin resistance, and dyslipidemia are
key obesity-associated risk factors for cardiovascular dis-
eases. We found that both fasting and nonfasting blood
glucose levels were lower in both male and female fatVHLko
mice (Figure 9A and 9B). Consistent with these ﬁndings,
Matsuura et al have also shown that genetic deletion of prolyl
hydroxylase 2 (Phd2), a negative regulator of HIF-a, in
adipocytes improves glucose tolerance and homeostasis.31
Nonetheless, the relative rates of change in blood glucose
concentrations in response to glucose or insulin challenge
were comparable between fatVHLko mice and WT littermates
(Figure 10A and 10B). Although hyperglycemia and insulin
resistance have been considered risk factors for cardiovas-
cular disease, our observations demonstrate, rather surpris-
ingly, that HIF activation in adipocytes can cause pathological
cardiomegaly independent of insulin resistance and glucose
intolerance.
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Using cDNA microarrays, we found that several apolipo-
proteins (Apoa5, Apoc4, and Apom) and lipoprotein lipase
inhibitor Angptl3 were signiﬁcantly downregulated in fatVHLko
adipose tissue (Table 4), suggesting compromised lipid
transport and metabolism in adipocytes. Reduced expression
of Ppargc1a (peroxisome proliferator-activated receptor-c
coactivator 1a) and Ucp1 (uncoupling protein 1) suggests
repressed mitochondrial function and thus decreased lipid
oxidation. Furthermore, decreased expression of glycerol
phosphate dehydrogenase 2 (Gpd2) and glycerol kinase (Gyk)
Figure 7. Echographic and in vivo hemodynamic analyses reveal cardiac dysfunction in fatVHLko and fatVHL1Ako mice. Procedures were
performed on lightly anesthetized mice at 8 weeks of age, except that fatVHL1Ako and their WT littermates were at 4 weeks of age. For
statistical analysis of multiple data groups (left panels), 1-way ANOVA was used with post hoc Dunnett’e multiple comparison test. Student’s t-test
was used for 2-group comparison (right panels). Echocardiography is shown in A through D with n=9 for fatVHLwt, n=7 for fatVHLko, n=4 each for
fatVHL2Ako and fatVHL1A2Ako. For fatVHL1Ako comparison, n=5 each for fatVHL1Ako and fatVHLwt. A, Cardiac dimensions: LVPW, left ventricle
posterior wall; IVS, interventricular septum; LVID, left ventricle internal dimension; d, diastolic; s, systolic. Left panel: P<0.02 (1-way ANOVA) for
each group except IVSs, *P<0.05 vs fatVHLwt and ^ vs fatVHLko. Right panel: *P<0.05 and **P<0.01 for fatVHL1Ako vs fatVHLwt. B, Left
ventricle (LV) mass. For the left panel, P<0.0001 (1-way ANOVA) with signiﬁcant difference vs fatVHLwt (*) or vs fatVHLko (^). For the right panel
comparing fatVHL1Ako to fatVHLwt, ***P<0.001 (t-test). C, Cardiac volumes (LVEDV, LV end diastole volume and LVESV, LV end systole volume).
For the left panel, P<0.02 (1-way ANOVA). D, Changes in ejection fraction (EF) and fractional shortening (FS). For the left panel, P<0.01 (%EF, 1-
way ANOVA) and *P<0.05 vs fatVHLwt. Hemodynamic analysis (catheter) is shown in E through H with n=8 for fatVHLwt, n=6 for fatVHLko, n=9
for fatVHL2Ako, n=6 for fatVHL1A2Ako, n=4 for fatVHL1Ako, and n=5 for fatVHLwt. E, End systolic pressure (ESP). For the left panel, P=0.065 (1-
way ANOVA). For the right panel comparing fatVHL1Ako to fatVHLwt, ***P<0.05 (t-test). F, End diastolic pressure (EDP). For the left panel,
P=0.01 (1-way ANOVA) and *P<0.05 vs fatVHLwt. G, Positive pressure changes during heart cycles (+dP/dt maximum). For the left panel,
P<0.005 (1-way ANOVA), *P<0.05 vs fatVHLwt and ^P<0.05 vs fatVHLko. H, Negative pressure changes (dP/dt minimum). For the left panel,
P<0.001 (1-way ANOVA), *P<0.05 vs fatVHLwt and ^P<0.05 vs fatVHLko. For the right panel comparing fatVHL1Ako to fatVHLwt, *P<0.05
(t-test). KO indicates knockout; VHL, von Hippel–Lindau; WT, wild type.
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suggests compromised glycerol and lipid metabolism in
adipocytes (Table 4). Expression of several representative
genes was further validated by qRT-PCR (Figure 9C). Using
in vitro-derived adipocytes, we found that Apoc4, Angptl3,
Gpd2, and Gyk were strongly downregulated by hypoxia,
whereas Apoa5 and Apom were not signiﬁcantly affected
(Figure 9D), indicating that hypoxia alone can repress
expression of lipid metabolism genes in adipocytes. Further-
more, circulating levels of glycerol were increased in both
fatVHLko and fatVHL1Ako mice but were nearly normalized in
fatVHL2Ako and fatVHL1A2Ako mice (Figure 9E). However,
serum triglyceride levels were not changed signiﬁcantly in
these KO mice (Figure 9F). The latter ﬁnding was consistent
with the lack of lipid deposition either in the aortas
(Figure 10C) or in the heart, liver, and skeletal muscle from
fatVHLko mice (Figure 3F). These results suggest that HIF
activation in adipocytes can lead to the development of
pathological cardiac hypertrophy independent of hyperlipid-
emia and atherosclerotic lesions.
Activation of the Adipocyte HIF-2 Pathway
Results in Adipose Inﬂammation
Obesity often leads to chronic inﬂammation in adipose tissue
with increased production of inﬂammatory cytokines including
IL-1, IL-6, and TNF-a.5,6 The HIF pathway plays an important
role in inﬂammatory responses. First, HIF-1 regulates the
transcription of several important inﬂammatory genes,32,33
including inducible nitric oxide synthase (Nos2), macrophage
migration inhibitory factor (Mif), and transforming growth
factor (Tgfb). Second, several types of inﬂammatory cytokines
can increase HIF-1a expression and its transcription
Figure 8. Heart rates and blood pressures of transgenic mice. Heart rates (A) and blood pressures (B and C) were measured using a catheter after
bilateral vagus nerves were severed. Mice were 8 weeks old except that the fatVHL1Ako and their wild-type littermates were 4 weeks old at the time
of examination. n=8 for fatVHLwt, 6 for fatVHLko, 9 for fatVHL2Ako, 6 for fatVHL1A2Ako, 4 for fatVHL1Ako, and 5 for fatVHLwt. No signiﬁcant
differences were found between fatVHLwt and each of the transgenic groups. KO indicates knockout; VHL, von Hippel-Lindau; WT, wild type.
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Figure 9. Effects of Vhl deletion in adipocytes on glucose and lipid metabolism. A, Glucose tolerance tests (GTTs) were performed after 14 to
16 hours overnight fasting (n=3 each group, except n=4 for female fatVHLko mice). B, Insulin tolerance tests (ITTs) were performed on
postprandial mice (n=5 for female and 4 for male mice). C, Quantitative analysis of selective metabolism genes in adipose tissue (n=3 mice) and
(D) in vitro hypoxia-treated adipocytes (n=3 experiments) by real-time RT-PCR. *P<0.05 (t-test). E, Serum glycerol and (F) total triglycerides were
measured in non-fasted mice (n=16 to 27). In E, P<0.0001, 1-way ANOVA with signiﬁcant difference between fatVHLko (**) or fatVHL1Ako (*) vs
fatVHLwt, and signiﬁcance (^) between fatVHLko vs fatVHL2A or fatVHL1A2A (Dunnett’s multiple comparison). In F, P=0.16 (1-way ANOVA).
Angptl3 indicates angiopoietin-like 3; Apoa5, apolipoprotein A-V; Apoc4, apolipoprotein C-IV; Apom, apolipoprotein M; Gpd2, glycerol phosphate
dehydrogenase 2; Gyk, glycerol kinase; KO, knockout; Lep, leptin; Ppargc1a, peroxisome proliferative activated receptor c coactivator 1a; VHL, von
Hippel–Lindau; WT, wild type.
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activities.34 Among them, IL-1, IL-6, TNF-a, and transforming
growth factor-b are robustly increased in adipose tissue with
obesity and in hypoxia-treated adipocytes.6 These observa-
tions strongly suggest existence of a positive feedback loop
between HIF and inﬂammatory cytokines.
The fatVHLko mice showed higher numbers of circulating
lymphocytes and monocytes (Figure 11A and 11B), suggest-
ing an inﬂammatory state. Compared with the WT controls,
immunoglobulin genes were the most increased genes in
fatVHLko adipose tissue (>5-fold, Table 5), suggesting signif-
icant inﬁltration of leukocytes that likely resulted from
increased expression of a large number of chemokines
including MCPs (Ccl2, Ccl7, and Ccl8) and MIP-1a (Ccl3) in
fatVHLko fat (Table 5 and Figure 11C). We also found that
Il1b, Il6, Mmp9, and Tnf were signiﬁcantly upregulated in
fatVHLko fat (Figure 11C). Interestingly, these inﬂammation-
related genes are also strongly increased in fat tissues of
obese humans and/or mice.6,25 Furthermore, elevated
expression of Emr1 (F4/80) suggests increased macrophage
inﬁltration in adipose tissue (Figure 11C). Using in vitro-
derived adipocytes, we found that hypoxia signiﬁcantly
increased the expression of Il6, Mmp9, Tnf, and Ccl genes
(Figure 11D). Again, concomitant deletion of Hif2a but not
Hif1a in adipocytes led to reduced expression of key
inﬂammatory genes, especially Tnfa and Pai1 (plasminogen
activator inhibitor 1), in adipose tissue (Figure 11E). These
observations strongly suggest that adipocyte HIF-2a plays a
dominant role in mediating adipocyte-dependent inﬂammatory
responses.
It is likely that circulating factors secreted either directly by
adipose or indirectly by other tissues are key contributors to
the development of pathological cardiac hypertrophy in
fatVHLko and fatVHL1Ako mice. Hence, we determined the
serum concentrations of relevant inﬂammatory cytokines
using a quantitative multiplexed cytokine assay (Bio-Plex, Bio-
Rad). From a panel of 15 representative cytokines (see
Methods for details), those with signiﬁcant changes are
shown in Figure 11F and 11G. Notably, the circulating levels
of IL-1b and MCP-1 were signiﬁcantly increased in both
fatVHLko and fatVHL1Ako mice (Figure 11F), correlating well
with gross cardiomegaly. Interestingly, deletion of adipocyte
Hif2a reduced the serum levels of IL-1b and MCP-1/
chemokine (C-C motif) ligand 2 (CCL2) to those in fatVHLwt
mice (Figure 11F), consistent with the normal heart pheno-
type found in fatVHL2A and fatVHL1A2Ako mice. These data
strongly suggest that IL-1b and MCP-1/CCL2 have the
potential to facilitate the development of pathological cardiac
hypertrophy. On the other hand, IL-6, IFNc, MIP-1b, and TNF-a
are not likely to be key factors of cardiomegaly because their
serum levels in fatVHL1Ako mice are not signiﬁcantly different
from those of the WT controls as well as the asymptomatic
fatVHL2Ako and fatVHL1A2Ako mice (Figure 11F). Neverthe-
Figure 10. Metabolic and aortic phenotypes of transgenic mice. A, Glucose tolerance tests (GTTs) were performed after 14 to 16 hours
overnight fasting (n=3 each group, except n=4 for female fatVHLko mice). B, Insulin tolerance tests (ITTs) were performed on postprandial mice
(n=5 for female and 4 for male mice). Changes in glucose concentrations were shown as relatvie values with respective starting glucose value as
100. C, Genetic deletion of Vhl in adipocytes does not lead to intra-aortic lipid deposition (an atherosclerotic lesion). Aortas were isolated from
mice of indicated genotypes and ﬁxed in 4% paraformaldehyde. Periaortic fat tissue was removed under a dissecting microscope. Aortas were
opened lengthwise and then stained in an Oil Red O staining solution for 1 hour. Microscopic inspection found no presence of lipid deposits or
atherosclerotic lesions on the inner surface of aortas. The red stain in the micrographs came from residual periaortic fat tissue. KO indicates
knockout; VHL, von Hippel–Lindau; WT, wild type.
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Table 4. Metabolism Genes Differentially Regulated in fatVHLko Adipose Tissue (n=3)
Gene NCBI Accession FDR Adjusted P Value Fold-Change (KO vs WT)
Aldh3b2 (aldehyde dehydrogenase) NM_001177438 0.011 3.73
Slc2a3 (solute carrier family 2, member 3 or Glut3) NM_011401 0.007 3.26
Slc25a10 (mitochondrial carrier, dicarb) NM_013770 0.021 3.23
Slc27a1 (fatty acid transporter) NM_011977 0.004 3.22
Lep (leptin) NM_008493 0.047 3.08
Fads3 (fatty acid desaturase 3) NM_021890 0.029 2.80
Aldh1 l1 (aldehyde dehydrogenase 1 family, member L1) NM_027406 0.007 2.52
Abcd2 (ATP-binding cassette, subfamily D, member 2 or Aldl1 or Aldrp) NM_011994 0.034 2.28
Fmo2 (flavin containing monooxygenase) NM_018881 0.025 2.22
Cbr3 (carbonyl reductase) NM_173047 0.018 2.20
Gpx8 (glutathione peroxidase) NM_027127 0.004 2.09
Fads1 (fatty acid desaturase 1) NM_146094 0.025 2.08
Pxmp2 (peroxisomal membrane protein) NM_008993 0.006 2.01
Ndufa4l2 (NADH dehydrogenase [ubiquinone] 1a subcomplex) NM_001098789 0.007 2.01
Gpd2 (glycerol phosphate dehydrogenase) NM_010274 0.006 2.01
Pgam2 (phosphoglycerate mutase) NM_018870 0.038 2.01
Pfkl (phosphofructokinase) NM_008826 0.004 2.07
Fabp3 (fatty acid binding protein 3) NM_010174 0.020 2.08
Acsm1 (acyl-CoA synthetase medium-chain family) NM_054094 0.035 2.16
Ppargc1a (peroxisome proliferative activated receptor g coactivator 1a) NM_008904 0.018 2.21
Ptger3 (prostaglandin E receptor) NM_011196 0.015 2.23
Acsl5 (acyl-CoA synthetase long-chain family) NM_027976 0.004 2.46
Apoa5 (apolipoprotein A-V) NM_080434 0.017 2.54
Ahcy (S-adenosylhomocysteine hydrolase) NM_016661 0.016 2.64
Slc3a1 (solute carrier family 3, member 1) NM_009205 0.036 2.64
Slc27a5 (solute carrier family 27 [fatty acid transporter], member 5) NM_009512 0.031 2.81
Akr1c14 (aldo-keto reductase family) NM_134072 0.031 2.84
Apom (apolipoprotein M) NM_018816 0.038 3.01
Me3 (malic enzyme) NM_181407 0.006 3.38
Upp2 (uridine phosphorylase) NM_029692 0.038 3.42
Gyk (glycerol kinase) NM_212444 0.022 3.43
Aldh8a1 (aldehyde dehydrogenase 8 family, member A1) NM_178713 0.038 3.56
Apoc4 (apolipoprotein C-IV) NM_007385 0.033 3.57
Ugt3a1 (UDP glycosyltransferase 3a1) NM_207216 0.047 3.95
G6pc (glucose-6-phosphatase) NM_008061 0.032 4.03
Angptl3 (angiopoietin-like 3) NM_013913 0.042 4.06
Aass (aminoadipate-semialdehyde synthase) NM_013930 0.030 4.64
Elovl2 (elongation of very long chain fatty acids) NM_019423 0.027 4.64
Ugt3a2 (UDP glycosyltransferase 3a2) NM_144845 0.040 5.50
Ugt2a3 (UDP glycosyltransferase 3a2) NM_028094 0.026 6.20
Akr1c6 (aldo-keto reductase family) NM_030611 0.040 8.05
Ucp1 (uncoupling protein) NM_009463 0.004 13.10
FDR indicates false discovery rate; KO, knockout; NCBI, National Center for Biotechnology Information; WT, wild type.
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Figure 11. Activation of the adipocyte HIF-2 pathway increases inﬂammatory cytokine expression. Analysis of circulating lymphocytes (A) and
monocytes (B). *P<0.05 vs WT (t-test). n=3 (female KO), 5 (female WT), 4 (male KO), and 6 (male WT), respectively. Quantitative analysis of
selective inﬂammatory cytokines in (C) adipose tissue (n=3 mice) and (D) in vitro hypoxia-treated adipocytes by real-time RT-PCR, n=3
experiments, *P<0.05 vs 21% O2 (t-test). E, Concomitant Hif2a deletion in adipocytes reduces the expression of inﬂammatory cytokines in
adipose tissue. Total RNA was prepared from interscapular fat pads and was subjected to quantitative RT-PCR. P<0.025 (1-way ANOVA) for each
gene category except Il1b (P=0.26); fatVHLwt: n=13; fatVHLko: n=5; fatVHL1Ako: n=5; fatVHL2Ako: n=7; fatVHL1A2Ako: n=5. Signiﬁcance within
each gene category: * vs fatVHLwt; # vs fatVHLko or fatVHL1Ako; ^ vs fatVHLko, and@ vs fatVHL1Ako (Dunnett’s multiple comparison). F and G,
Quantitative multiplexed cytokine assay (n=12 per genotype). For the IL-1b, IL-6, IFNc, and MCP-1 group, P<0.05 (1-way ANOVA with Fisher’s LSD
test for multiple comparison). For the MIP-1b, TNFa, and IL-12p70 group, P<0.05 (Kruskal–Wallis test with Dunn’s multiple-comparison test).
Signiﬁcant pairwise differences within each cytokine category: * vs fatVHLwt; # vs fatVHLko or fatVHL1Ako; and ^ vs fatVHLko. No signiﬁcant
differences were found in the IL-12p40 group (P=0.35, 1-way ANOVA). Ccl2 indicates chemokine (C-C motif) ligand 2; HIF, hypoxia-inducible
factor; IFNc, interferon c; IL, interleukin; KO, knockout; TGF, transforming growth factor; TNFa, tumor necrosis factor a; VHL, von Hippel–Lindau;
WT, wild type.
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less, these data demonstrate that expression of IL-6, IFNc,
and TNF-a is likely dependent on the transcription activities of
both HIF-1 and HIF-2 in adipocytes.
It is very interesting that serum concentrations of the
biologically active IL-12-p70 (IL-12ab heterodimer) in fat-
VHL1Ako mice were signiﬁcantly higher than the WT control
andmoderately higher than fatVHLko (Figure 11G). In contrast,
serum concentrations of the inactive IL-12-p40 (IL-12b) did not
change much among these mice. These observations suggest
that IL-12p70, a proinﬂammatory cytokine secreted by B cells,
dentritic cells, and macrophages, may potentially exacerbate
hypertrophic heart conditions in fatVHL1Ako mice. However, it
is possible that other yet unidentiﬁed cytokines, chemokines,
and/or adipokines are also involved in the development of
hypertrophic cardiac dysfunctions in the mice with HIF-2
activation in adipocytes.
NF-jB and NFAT Pathways Are Activated in the
Heart
Studies have shown that NF-jB activation signiﬁcantly con-
tributes to the development of cardiac hypertrophy.35,36
Consistent with the increased expression of proinﬂammatory
genes in adipose tissue and higher levels of circulating
cytokines, we found strongly elevated protein levels of p50
NF-jB and its p105 precursor in fatVHLko and fatVHL1Ako
hearts (Figure 12A), indicating NF-jB activation. Interestingly,
levels of p50 and p105 in both fatVHL2Ako and fatVHL1A2Ako
hearts were reduced by and large to those found in the WT
controls. On the other hand, levels of p65 RelA appeared to be
regulated by both HIF-dependent and -independent mecha-
nisms because deletion of both Hif1a and Hif2a failed to fully
normalize p65 levels in the fatVHL1A2Ako heart (Figure 12A).
The NFAT pathway plays a prominent role in the develop-
ment of pathological cardiac hypertrophy.37 Regulator of
calcineurin 1-4 (Rcan1-4), but not Rcan1-1, is one of the key
NFAT target genes.38 We found that Rcan1-4 expression was
increased >3-fold in the heart of fatVHLko and fatVHL1Ako
mice (Figure 12B). Again, Hif2a deletion in adipocytes strongly
reduced Rcan1-4 expression in the heart, although adipocyte
HIF-1a also appeared to be involved in the upregulation of
cardiac Rcan1-4 (Figure 12B). On the other hand, expression of
Rcan1-1 and Nfatc1-Nfatc4 was only moderately (≤2-fold)
affected (Figure 12B and 12C). Our results are consistent with
the recent ﬁnding that NF-jB interacts with and activates NFAT
to promote cardiac hypertrophy.36
Table 5. Inﬂammatory/Immune Genes Differentially Regulated in fatVHLko Adipose Tissue (n=3)
Gene Symbol Gene Name NCBI Accession FDR Adjusted P Value Fold-Change (KO vs WT)
Igk-V1 Z95477 0.0019 20.42
Igk BC128281 0.0052 11.92
Igk-V28 DQ078272 0.0042 8.88
Igkv4-71 NC_000072 0.0039 8.77
Igj NM_152839 0.0056 7.29
Igh BC092065 0.0236 7.19
Igk-V19-14 U59155 0.0065 6.48
Igl-V2 NC_000082 0.0025 3.05
Ccl8 (MCP-2) Chemokine (C-C motif) ligand 8 NM_021443 0.0160 3.65
Ccl7 (MCP-3) Chemokine (C-C motif) ligand 7 NM_013654 0.0177 2.73
Ccl3 (MIP-1a) Chemokine (C-C motif) ligand 3 NM_011337 0.0309 2.46
Ccl2 (MCP-1) Chemokine (C-C motif) ligand 2 NM_011333 0.0267 2.32
Ccl24 (MPIF-2) Chemokine (C-C motif) ligand 24 NM_019577 0.0041 2.25
Ccl6 (MRP-1) Chemokine (C-C motif) ligand 6 NM_009139 0.0115 2.01
Cxcl9 (Mig) Chemokine (C-X-C motif) ligand 9 NM_008599 0.0285 2.00
Ifi27l2a Interferon a–inducible protein 27 like 2A NM_029803 0.0255 2.54
Vcam1 Vascular cell adhesion molecule 1 NM_011693 0.0086 2.30
Cd53 CD53 antigen NM_007651 0.0076 2.25
Cd93 (Ly68) CD93 antigen NM_010740 0.0083 2.10
Ly86 (MD1) Lymphocyte antigen 86 NM_010745 0.0055 2.09
FDR indicates false discovery rate; KO, knockout; NCBI, National Center for Biotechnology Information; WT, wild type.
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Based on these observations, we propose a multistage
mechanism (Figure 12D). (1) Sustained activation of HIF-2
transcription factor pathway in adipocytes results in disregu-
lated expression of adipocyte-derived genes. (2) These adipo-
cyte-produced factors induce local inﬂammation via
recruitment of macrophages and other leukocytes. (3) The
inﬂamed adipose tissue secretes adipokines and other proin-
ﬂammatory cytokines/chemokines into the circulation. (4)
These circulating factors then induce the pathological cardiac
hypertrophy in part via activation of the NF-jB–NFAT pathway.
However, we cannot rule out the possibility that NF-jB
activation is downstream of cardiomyocyte hypertrophy.39
Other mechanisms are also likely to be involved due to the wide
ranges of target genes that can be induced directly or indirectly
by the HIF-2 transcription factor pathway in adipocytes.
Discussion
Our ﬁndings presented herein have uncovered a previously
unappreciated transcription factor pathway, mediated by HIF-
2 in adipocytes, that plays a critical role in the regulation of
adipocyte functions. Chronic activation of HIF-2, but not HIF-
1, in adipocytes leads to adipose inﬂammation and patholog-
ical hypertrophy in the heart. The hypertrophic heart condi-
tions presented by our mouse models are reminiscent of the
cardiac hypertrophy observed in severely obese persons.2 Our
solid genetic evidence strongly suggests that adipose hypoxia,
observed under the condition of pathological obesity,5–7 may
facilitate the development of obesity-related cardiac hyper-
trophy via sustained activation of HIF-2 in adipocytes.
Our ﬁndings demonstrate that HIF activation in adipocytes
exerts its cardiac effects in a manner distinct from other
purported mechanisms linked to obesity-associated cardio-
myopathy. The pathological cardiomegaly observed herein
occurs in the absence of lipid accumulation in blood vessels,
atherosclerosis, coronary occlusion, insulin resistance, and
glucose intolerance. Despite gross cardiomegaly, fatVHLko
and fatVHL1Ako mice do not present severely compromised
heart functions except reduced diastolic dP/dt values,
which is consistent with the report that obese persons exhibit
diastolic dysfunction even without hypertension,29 as well as
the ﬁnding that obese persons develop ventricular hypertro-
phy and congestive heart failure without other types of heart
disease.2,30 Our ﬁndings are also consistent with the clinical
Figure 12. Activation of the NF-jB and NFAT pathways in the heart is associated with cardiac hypertrophy. A, Heart tissue extracts from
indicated genotypes were subjected to Western blot analyses. Similar results were obtained in 4 independent sets of experiments. B and C, Total
RNA was prepared from heart (n=6 to 8 mice) and was subjected to quantitative RT-PCR using gene-speciﬁc primers as indicated. One-way
ANOVA: P≤0.01 for Rcan1-4, Nfatc2, and Nfatc3, but no statistical signiﬁcances found for Rcan1-1, Nfatc1, and Nfatc4. Signiﬁcant pairwise
differences within each gene category, * vs fatVHLwt and ^ vs fatVHLko (Dunnett’s multiple-comparison test). D, A potential mechanism
underlying the development of pathological cardiohypertrophy caused by HIF-2a activation in adipose tissue. HIF indicates hypoxia-inducible
factor; IL, interleukin; KO, knockout; NF-jB, nuclear factor–jB; NFAT, nuclear factor of activated T cells; Rcan, regulator of calcineurin; RelA, avian
reticuloendotheliosis viral oncogene (v-rel) homolog A; VHL, von Hippel–Lindau; WT, wild type.
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and epidemiological observations that obesity is signiﬁcantly
correlated with LV dysfunction and heart failure independent
of other established risk factors including diabetes, hyperten-
sion, and coronary artery disease.1 Furthermore, a recent
clinical study has found that LV mass continues to decline in
bariatric surgery patients long after weight loss and systemic
metabolism have plateaued,40 suggesting a potential involve-
ment of adipocyte-derived factors in the development of LV
hypertrophy independent of metabolic disorders.
Several mechanisms have been proposed to explain the
association between obesity and cardiac dysfunction, includ-
ing cardiac lipotoxicity secondary to abnormalities in lipid
metabolism, hypertrophy due to a chronically increased
cardiac output or obesity-associated hypertension, and the
effects of hypoventilation, metabolic shifts, and coronary
disease associated with obesity.1 Other studies have shown
that obesity-induced changes in adipose tissue biology,
particularly the induction of chronic inﬂammation and altered
metabolism, may play a critical role in the development of
cardiovascular disease.3 Indeed, it has been established that
adipose tissue inﬂammation is a prominent clinical feature of
obesity,5–7 although the mechanisms driving adipose inﬂam-
mation as well as those underlying the pathological effects of
adipose-derived proinﬂammatory factors in other organs
remain to be fully elucidated. The exact mechanism under-
lying adipocyte HIF-driven hypertrophic heart disease is likely
to be complex and may involve multiple adipose tissue–
derived factors, as well as secondary effects by other tissues
under the inﬂuence of the altered adipose tissue functions.
Nonetheless, our ﬁndings suggest a new model wherein HIF-2
activation in adipocytes leads to increased expression and
secretion of multiple proinﬂammatory cytokines and chemo-
kines that activate the NF-jB and NFAT pathways in the
myocardium to facilitate the development of pathological
cardiac hypertrophy.
In support of this model, we ﬁnd that deletion of Vhl in
adipocytes increases the expression of a wide range of
inﬂammatory cytokines and chemokines, including Il1b, Il6,
Tnf, MCPs (Ccl2, Ccl7, Ccl8), and MIP-1a (Ccl3). Expression of
these genes is also signiﬁcantly increased in fat tissues of
obese humans and/or mice.6,25 We also ﬁnd that the elevated
serum concentrations of IL-1b, MCP-1/CCL2, and IL-12p70
strongly correlate with the pathological cardiac hypertrophy in
fatVHLko and fatVHL1Ako mice. Consistent with our ﬁndings,
signiﬁcantly elevated serum MCP-1/CCL2 levels were found
in both obese children41 and obese adults,42 as well as in
obese ob/ob mice.43 Increased serum IL-12 levels are also
found in obese adults.44 Furthermore, expression of Il1b and
Ccl2/Mcp1 is strongly increased in hypertrophied rat heart,45
and signiﬁcantly higher IL1b expression is also reported in
heart biopsy from patients with dilated cardiomyopathy.46 It is
also reported that IL-1b can induce hypertrophic response in
cardiomyocytes.47 In addition, our data show that fatVHL1Ako
mice have the highest serum levels of the biologically active
IL-12p70, suggesting a potentially important role of IL-12p70
in exacerbating the pathological conditions induced by
adipocyte HIF activation. It is, however, worth noting that,
although being associated with inﬂammatory heart dis-
eases,48 elevated serum levels of IL-6, IFNcc, and TNFa are
not critically involved in the development of fatal cardiac
hypertrophy and dysfunction in fatVHL1Ako mice. Our
ﬁndings do suggest that multiple circulating cytokines and
chemokines, including IL-1b, MCP-1/CCL2, IL-12-p70, and
those yet to be identiﬁed, are involved in induction of
hypertrophic myocardial dysfunctions resulting from the
activated HIF-2 pathway in adipocytes.
We also ﬁnd that fatVHLko mice have signiﬁcantly
increased adipose expression of Hmox1, Lep, Vegfd/Figf,
and Serpine1/Pai1, whose expression is commonly found in
adipose tissue of obese mice and humans.6,25 It is worth
noting that adipose expression of adiponectin (Adipoq) is not
signiﬁcantly affected by Vhl deletion according to cDNA
microarray analysis. Interestingly, Lep and Serpine1/Pai1
have been established as independent risk factors for heart
disease.49 The fatVHLko and fatVHL1Ako mice also have
increased angiogenesis in multiple tissues including heart and
fat, likely due to increased expression of several proangio-
genic genes including Lep, Plgf, and Vegfd/Figf (but not Vegfa)
in adipose tissue. It is interesting that angiogenesis is
reportedly sufﬁcient to induce myocardial hypertrophy in the
absence of other cardiac stresses,50 thus raising the question
of whether this mechanism contributes to the cardiac
hypertrophy observed in obesity. It is also possible that the
increased cardiac vascularity noted in this study is compen-
satory, rather than causative, to cardiac hypertrophy primarily
induced by circulating proinﬂammatory cytokines. However,
the effects of both proangiogenic factors and proinﬂammatory
cytokines are likely responsible for the pathological cardiac
hypertrophy observed in fatVHLko and fatVHL1Ako mice.
In summary, our data have revealed previously unrecog-
nized roles of HIF-1a and HIF-2a in mediating the effects of
Vhl deletion in adipocytes. Speciﬁcally, the HIF-2 transcription
factor pathway constitutes a critical stress–response mech-
anism in adipocytes, and chronic HIF-2 activation in adipo-
cytes may play a dominant role in the development of
pathological cardiac hypertrophy associated with severe
obesity.
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